-
Wedbush Starts Iveric Bio Coverage With Bullish Rating On Zimura's Upcoming Pivotal Study
Tuesday, January 7, 2020 - 1:26pm | 250Read More...Iveric Bio Inc’s (NASDAQ: ISEE) lead asset, Zimura, could begin a pivotal clinical study in the geographic atrophy market in the quarter, according to Wedbush. The Analyst Wedbush’s David Nierengarten initiated coverage of Iveric Bio with an Outperform rating and a price target of...
-
Do Analysts See A Path Forward For Ophthotech's Fovista?
Friday, March 24, 2017 - 3:35pm | 452Read More...After the release of Ophthotech Corp (NASDAQ: OPHT)'s fourth-quarter results, Leerink weighed in on the possibility of a path forward for Fovista, the company's candidate for the treatment of wet age-related macular degeneration. The Disappointment The company announced disappointing...
-
Ophthotech's Fovista Has Potential To Break Through The 'Therapeutic Ceiling' Of Anti-VEGF Therapies
Friday, August 19, 2016 - 10:48am | 401Read More...BTIG’s Ling Wang believes Ophthotech Corp (NASDAQ: OPHT)'s Fovista has the potential to “break through the therapeutic ceiling of current anti-VEGF therapies.” Wang initiated coverage of the company with a Buy rating and price target of $92. Key Catalysts “We view the...
